---
figid: PMC11201201__biomedicines-12-01328-g005
figtitle: Marketed drugs targeting the VEGF/VEGFR axis and its downstream signaling
  pathway
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11201201
filename: biomedicines-12-01328-g005.jpg
figlink: /pmc/articles/PMC11201201/figure/F5
number: F5
caption: 'Marketed drugs targeting the VEGF/VEGFR axis and its downstream signaling
  pathway. Figure presents drugs marketed around the world with principal mode of
  action grouping them into ones that act on interaction of VEGF and VEGF-R, those
  that inhibit tyrosine kinase and those that interact or block downstream signaling
  through one of the three major pathways. Reproduced with permission from Wang, L.,
  Liu, W-Q., Broussy, S. Han, B. and Fang H. Recent advances of anti-angiogenic inhibitors
  targeting VEGF/VEGFR axis. Front Pharmacol, 2024, 14, 1307860, doi: 10.3389/fphar.2023.1307860
  [46]'
papertitle: Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the
  Pathogenesis of iMCD-TAFRO
reftext: Gordan Srkalovic, et al. Biomedicines. 2024 Jun;12(6).
year: '2024'
doi: 10.3390/biomedicines12061328
journal_title: Biomedicines
journal_nlm_ta: Biomedicines
publisher_name: MDPI
keywords: VEGF | TAFRO | i-MCD | IL-6 | mTOR | signaling pathways
automl_pathway: 0.8491316
figid_alias: PMC11201201__F5
figtype: Figure
redirect_from: /figures/PMC11201201__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11201201__biomedicines-12-01328-g005.html
  '@type': Dataset
  description: 'Marketed drugs targeting the VEGF/VEGFR axis and its downstream signaling
    pathway. Figure presents drugs marketed around the world with principal mode of
    action grouping them into ones that act on interaction of VEGF and VEGF-R, those
    that inhibit tyrosine kinase and those that interact or block downstream signaling
    through one of the three major pathways. Reproduced with permission from Wang,
    L., Liu, W-Q., Broussy, S. Han, B. and Fang H. Recent advances of anti-angiogenic
    inhibitors targeting VEGF/VEGFR axis. Front Pharmacol, 2024, 14, 1307860, doi:
    10.3389/fphar.2023.1307860 [46]'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - DLL4
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - KDR
  - FLT1
  - FLT4
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - NCK1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - CRK
  - MAPK14
  - MAPK1
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK3
  - MAPKAPK2
  - MTOR
  - TK1
  - TK2
  - RAS
  - MEK
  - inhibitors
  - Sorafenib
  - Sunitinib
  - Nintedanib
  - Pazopanib
  - Lenvatinib
  - Vandetanib
  - Axitinib
  - Fruquintinib
  - Tivozanib
  - Regorafenib
  - Sotorasib
  - Selumetinib
  - Vemurafenib
  - Copanlisib
  - Dabrafenib
  - Trametinib
  - Cobimetinib
  - Binimetinib
  - Everolimus
  - Sirolimus
---
